July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Inhibitory Effect of Topical Thymosin beta 4 against Ocular Surface Inflammation in a Mouse Model of Experimental Dry Eye
Author Affiliations & Notes
  • Rujun Jin
    Ophthalmology, Chonnam National University Medical School & Hospital, Gwangju, Korea (the Republic of)
    Biomedical Sciences Graduate School, Chonnam National University, Korea (the Republic of)
  • Ying Li
    Ophthalmology, Chonnam National University Medical School & Hospital, Gwangju, Korea (the Republic of)
  • Lan Li
    Ophthalmology, Chonnam National University Medical School & Hospital, Gwangju, Korea (the Republic of)
    Biomedical Sciences Graduate School, Chonnam National University, Korea (the Republic of)
  • HYEON JEONG YOON
    Ophthalmology, Chonnam National University Medical School & Hospital, Gwangju, Korea (the Republic of)
  • In-Cheon You
    Ophthalmology, Chonbuk National University Hospital, Korea (the Republic of)
  • Kyung Chul Yoon
    Ophthalmology, Chonnam National University Medical School & Hospital, Gwangju, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Rujun Jin, None; Ying Li, None; Lan Li, None; HYEON JEONG YOON, None; In-Cheon You, None; Kyung Chul Yoon, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 269. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rujun Jin, Ying Li, Lan Li, HYEON JEONG YOON, In-Cheon You, Kyung Chul Yoon; Inhibitory Effect of Topical Thymosin beta 4 against Ocular Surface Inflammation in a Mouse Model of Experimental Dry Eye. Invest. Ophthalmol. Vis. Sci. 2019;60(9):269. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the therapeutic effect topical glycine-thymosine beta 4 (Gly-Tb4) eye drop in a mouse model of experimental dry eye (EDE).

Methods : Eye drops consisting of 0.05% cyclosporine A (CsA),0.1% Gly-Tb4, 0.1% wild-Tb4, or balanced salt solution (BSS) were applied for the treatment of EDE. Tear volume, tear film break-up time (TBUT), and corneal staining scores were measured 7 and 14 days after treatment. At day 14, levels of interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α and interferon(IFN)-γ were measured in the conjunctiva using a multiplex immunobead assay. Furthermore, flow cytometry, terminal deoxynucleotidyl transferase-mediated dUTP Nick-nick end labeling (TUNEL) staining, and periodic acid-Schiff (PAS) staining were performed at 14 days.

Results : The groups treated with 0.05% CsA and 0.1% Gly-Tb4 showed a significant improvement in tear volume and TBUT compared to the EDE and BSS groups at 7 and 14 days. Corneal staining scores significantly decreased in the 0.05% CsA, 0.1%, Gly-Tb4 0.1% and wild-Tb4 groups when compared to EDE and BSS groups at days 7 and 14. In addition, in the 0.05% CsA, 0.1%, Gly-Tb4 0.1% and wild-Tb4 groups, IL-1β, IL-6, TNF-α and IFN-γ levels, percentage of CD4+CCR5+Tcells and TUNEL positive cells were lower than in EDE and BSS groups. Compared to the EDE and BSS groups, the 0.05% CsA, 0.1%, Gly-Tb4 0.1% and wild-Tb4 groups showed a higher goblet cell density (p < 0.05).

Conclusions : Topical application of 0.1% Gly-Tb4 can markedly improve clinical signs and decrease inflammation in the ocular surface of EDE, suggesting that 0.1% Gly-TB4 eye drops may be used as a therapeutic agent for dry eye disease.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×